France: Attorneys obliged to invest in continuous training

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

France: Attorneys obliged to invest in continuous training

Since the beginning of this year following law n° 20104‐315 of March 11 2014 reinforcing the battle against counterfeiting, an article was introduced in the Intellectual Property Code regulating the IP profession stipulating that all qualified patent and trade mark attorneys (conseils en propriété industrielle) need to dedicate a significant part of their time to professional training.

This decision has been preceded by a hefty debate between professionals claiming that such an obligation should not be regulated but left to the initiative of each individual, and those claiming that it is a must, testifying to a strong willingness to maintain a high level of expertise all along one's career as an IP attorney.

The article L422‐10‐1 of the Intellectual Property Code stipulates that all French IP attorneys have to spend (at least) 20 hours per calendar year on on professional training.

Interestingly, four types of intervention can be taken into account to fulfil this obligation.

First of all one can fulfil this obligation by participating in training such as academic seminars or courses related to IP ‐ think of law changes or case law evolutions. Note that seminars or courses given by a qualified patent or trade mark attorney outside an academic environment can also qualify. It gives IP attorneys the possibility to follow specific training referring to specialised matters not (yet) dealt with by the academic world. Luckily the hours one commits to acting as a speaker on IP or teacher in the matter also count.

Finally, publishing articles or work related to IP, are also valid to comply with this training obligation The Compagnie Nationale des Conseils en Propriété Industrielle (CNCPI) will assess whether the

training obligation has been fulfilled by the IP practioners. However, the legal framework detailing the control of such obligation and the nature of the potential sanctions in case the obligation is not fulfilled still needs to be set up. For the most proactive French law firms these new rules just confirm what they are already promoting internally. On a wider scale, it shows the willingness of the French IP profession to ensure its expertise is continuously developed and kept up to date in an ever changing world.

Rolland_Jean

Jean‐Christophe Rolland


Gevers & Ores41, avenue de FriedlandParis 75008, FranceTel: +33 1 45 00 48 48Fax: +33 1 40 67 95 67paris@gevers.euwww.gevers.eu

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article